An observational study in Tuberculosis (TB), sponsored by University College, London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by University College, London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Tuberculosis with a site in United Kingdom — 8 open to participants now, 10 under way, none of them phase 3. Tuberculosis · United Kingdom.
Among the 66 studies in Tuberculosis with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2025, is one of 20 observational ones, and was the 63rd registered.
1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.
Browse Tuberculosis studies →8 of the 66 studies in Tuberculosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Liverpool School of Tropical Medicine · Sites in United Kingdom
Ages 18+
University of Oxford · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
University of Oxford · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Queen Mary University of London · Sites in United Kingdom
Ages 18+
University of Leicester · Sites in United Kingdom
Ages 16+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 6 · Phase 3 3
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 430 is above the median of 252 across 318 observational studies indexed under Tuberculosis.
Median enrollment 36 across the 46 interventional studies, 225 across the 20 observational. Of the 48 that completed or were terminated, 7 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 66 have an industry lead sponsor. The 10 most frequent:
University College, London is the lead sponsor of 652 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
University College, London has 4 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Tuberculosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07024836University College, LondonPRecision biomArker-Guided MAnagement of TuberculosIs Contacts: a Discrete Choice Experiment | 2026-12 |
| NCT06670755University of OxfordID93/GLA-SE Vaccination + BCG Challenge | 2027-07-31 |
| NCT06728930Queen Mary University of LondonEvaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 66 studies in Tuberculosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is part of a broader programme of work to develop and pilot a randomised-controlled trial of new tests to identify people who will benefit most from preventive treatment for tuberculosis (TB). The aim of the current study is to explore factors affecting patient decisions to start preventive treatment. The specific objectives are to understand how patients make decisions about preventive treatment initiation for TB (stage 1); and to design and conduct a "discrete choice experiment" survey to further evaluate preferences (stage 2).
We will perform up to 30 semi-structured interviews among people undergoing testing for latent TB infection, as part of routine clinical screening programmes (stage 1). Adults (aged ≥18 years) who have been or are being tested for LTBI in routine clinical services will be eligible for inclusion through purposive sampling. The findings from the qualitative study will then be used to inform the a discrete choice experiment (DCE). The DCE will be conducted to quantify the trade-off between future TB risk and preventive treatment acceptance, from patient and healthcare provided perspectives (stage 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Semi-structured interviews will first be conducted among 20-30 people undergoing testing for latent tuberculosis infection, as part of routine clinical screening programmes (Stage 1).
200 patients will then undertake a quantitative discrete choice experiment to evaluate preferences and trade-offs that influence acceptance of preventive TB treatment.
200 healthcare workers will also undertake a quantitative discrete choice experiment to evaluate preferences and trade-offs that influence recommendation of preventive TB treatment.
Preventive treatment acceptance
Discrete choice experiment data will be analysed to evaluate the primary outcome of preventive TB treatment acceptance in the survey.
Time frame: Baseline
Plan to share: Yes — Anonymised data from the discrete choice experiment will be made publicly available at the time of peer-reviewed publication.
Time frame: Indefinitely from the time of peer-reviewed publication.
Access criteria: The anonymised discrete choice experiment data will be publicly available
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.